ReviewJournal of gastroenterology and hepatology2026
Post-Translational Modifications in Pancreatic Cancer: Mechanisms to Clinical Applications.
Review in Journal of gastroenterology and hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, characterized by an extremely low 5-year survival rate. Its aggressiveness is attributed to early metastasis, rapid progression, and resistance to conventional therapies. Post-translational modifications (PTMs), which involve covalent modifications of amino acid residues, dynamically regulate protein activity, stability, and interactions. Increasing evidence has identified PTMs as key drivers in the pathogenesis of PDAC. PTMs encompass classical modifications such as phosphorylation, acetylation, glycosylation, ubiquitination, and methylation, as well as emerging modifications including SUMOylation, lysine crotonylation, and palmitoylation. This review first summarizes the mechanistic roles of both classical and novel PTMs in PDAC. It then explores the crosstalk among different types of PTMs and their integrated impact on PDAC progression. Finally, this review provides a theoretical basis for identifying early diagnostic biomarkers and potential targets for personalized therapy in PDAC. Overall, this work lays a conceptual foundation for future studies aimed at deciphering the complex PTM networks and their contributions to PDAC malignancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.